Beth Israel Deaconess Medical Center

BIDMC Investigator Contributes To FDA Approval of New and Better Way To Test Osteoporosis Treatments

BIDMC investigator Mary Bouxsein helped secure FDA approval of bone density imaging as a faster endpoint for osteoporosis ...

Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings ...

Foresee Pharmaceuticals announces the Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust LH Suppression with 6-Month Dosing Interval of leuprolide ...

FP-001 42 mg is an investigational, sustained-release formulation of a GnRH agonist being developed for the treatment of CPP. It is designed to provide continuous suppression of gonadotropin secretion ...
Medscape

FDA: BMD Can Be Surrogate Endpoint in Osteoporosis Trials

The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women.
The IslandOpinion

Why Somaliland Matters More Than Admitted

What if the most repeated claims about Somaliland are wrong? What if the idea that its separation is a recent rebellion, that ...
TipRanks on MSN

Lexaria Bioscience achieves primary endpoint in Phase 1b study GLP-1-H24-4

Lexaria Bioscience (LEXX) provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week ...
MedPage Today on MSN

FDA Opens Door to Quicker Approval of Osteoporosis Drugs

Although there are several effective anti-osteoporosis drugs on the market today, new therapies with improved safety profiles and efficacy are still needed. The FDA called osteoporosis-related ...

Lexaria Bioscience Corp.: Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to RybelsusDehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to RybelsusRecent financings create ...
Fierce Biotech

AstraZeneca flunks phase 3 lung cancer test in further setback to synthetic lethal mechanism

Susan Galbraith, AstraZeneca’s executive vice president for oncology haematology R&D, discussed the setback in a statement. Galbraith said the goal was to “reinvigorate the immune response of patients ...
Security Boulevard

Data Privacy vs Cybersecurity Solutions: Key Differences

Data privacy governs how organizations use and protect personal data under the law. Cybersecurity is about keeping systems and data safe from cyber threats. No. Cybersecurity solutions are essential, ...

‘Andor’ Season 2’s Opening Remains One of Its Best Moments

There are a lot of great moments across Andor season two—there’s a good reason that the show, one of our absolute favorites ...

FNIH Announces FDA Qualification of First Surrogate Endpoint for Use in Osteoporosis Clinical Trials

The Foundation for the National Institutes of Health (FNIH) announces that the Food and Drug Administration (FDA) has qualified the treatment-related change in hip bone mineral density (BMD) as a ...